Cancer can change as it grows and as it responds to treatment, but doctors cannot repeatedly remove tumor tissue every time they want an updated picture.
Scientists are therefore exploring whether an ordinary blood sample could provide a safer and easier window into what a tumor is doing.
A review from Karolinska Institutet describes a new generation of blood-based cancer analysis that combines several biological clues at once. The review was published in the medical journal Genome Medicine.
The idea builds on liquid biopsy, a technology that searches the bloodstream for material released by tumors. Unlike a traditional biopsy, which requires tissue to be removed from the body, a liquid biopsy can often begin with a standard blood draw.
This difference matters for patients. Tissue biopsies can involve needles, surgery or procedures that reach deep organs, and in some cases obtaining another sample later may be difficult or unsafe.
Blood can be collected repeatedly with much less burden. That gives researchers hope that liquid biopsies could eventually help doctors follow cancer over weeks, months or years rather than relying on occasional snapshots.
Current liquid biopsy tests often focus on particular signs of cancer, such as genetic changes in DNA released into the blood. But tumors are diverse, and no single biological signal tells the whole story.
The Karolinska team reviewed an approach that tries to collect many clues from one sample. The researchers refer to it as multifeature sequencing-based liquid biopsy, or MSLB.
Imagine trying to identify a person from only one clue compared with using their face, voice, fingerprints and other information together. The same general principle applies here: several weak or incomplete cancer signals may become more informative when they are analyzed as a group.
Blood contains small pieces of DNA that have been released by cells throughout the body. A fraction of this material can come from cancer cells, although finding it can be difficult, especially when a tumor is small.
Researchers can study more than the genetic spelling of this DNA. They can examine how long the fragments are, whether chromosomes show unusual changes and whether certain chemical marks appear on the DNA.
Those chemical marks include methylation, a normal system cells use to control genes. Cancer cells can develop abnormal methylation patterns, and these patterns may become useful fingerprints for detecting disease.
RNA in the blood can provide different information. Because RNA reflects which genetic instructions cells are using, changes in RNA may offer clues about the biological activity of a tumor.
Combining these sources could help scientists see cancer from several angles at once. Researcher Mariano A. Molina Beitia said analyzing multiple signals from the same blood sample may provide a fuller picture than examining each one separately.
The review points to studies that combined DNA methylation, fragment patterns and chromosome changes. Some reported encouraging results for finding different cancers, including disease at earlier stages.
Turning those signals into a useful answer is not simple. A single sample can generate a huge amount of information, so scientists increasingly use powerful computer analysis and machine learning to identify patterns hidden within the data.
Machine learning can be trained to recognize combinations associated with cancer, but it also creates important questions. A model that works well in one study may perform differently when tested in people of different ages, backgrounds or health conditions.
This is one reason the authors emphasize that much more validation is needed. Many studies so far have used limited patient groups, and researchers need larger forward-looking studies that test the technology under conditions closer to normal healthcare.
Laboratories also need shared rules for collecting blood, preparing samples, sequencing biological material and interpreting results. Small differences in these steps can affect what is detected and make comparisons between hospitals difficult.
Senior researcher Daniel Hagey said the field needs standardized workflows, independent validation and studies showing that patients actually benefit. Those requirements are crucial because detecting an unusual signal is not enough by itself to prove that acting on it will improve health.
The first widespread use may therefore not be screening healthy people for every possible cancer. The researchers suggest that monitoring people who already have a cancer diagnosis may be a more realistic early application.
For example, doctors might use repeated blood samples to see whether treatment is reducing cancer-related signals. They might also watch for biological changes that suggest a tumor is evolving or becoming resistant to a treatment.
Such monitoring could be especially helpful when a tumor is located somewhere that is difficult to biopsy repeatedly. It could also provide information more frequently than traditional tissue sampling.
The review presents an exciting direction, but it should not be interpreted as evidence that one blood test can already replace mammograms, colonoscopies, scans or tissue biopsies. The technology remains an active area of research, and false alarms or missed cancers could have serious consequences.
Its strongest near-term promise may be the ability to make cancer monitoring more dynamic. Instead of treating a tumor as something measured only at diagnosis, doctors might eventually be able to follow its changing biology through repeated blood samples.
Overall, the science is promising because it combines many pieces of information that cancer leaves behind. Whether this approach becomes a routine part of medicine will depend on larger studies, reliable standards, reasonable costs and, most importantly, evidence that the information helps patients live longer or receive better treatment.
If you care about cancer, please read studies that artificial sweeteners are linked to higher cancer risk, and how drinking milk affects risks of heart disease and cancer.
For more health information, please see recent studies about the best time to take vitamins to prevent heart disease, and results showing vitamin D supplements strongly reduces cancer death.
Source: Karolinska Institutet.
